KRAS and neoplasm: Of note, the substantial survival benefit and suppression of tumour growth, observed in sapitinib-treated VilCreER;Apcfl/+;KrasG12D/+;Alk5CA mice, is promising, particularly as the potency of EGFR-targeted therapies rapidly diminishes following Kras mutation46.